Look behind the lecture: paying for innovative therapies - why existing methods may not suffice

Research output: Other contribution

Abstract

In this feature, following his participation is a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting, Brian Godman discusses current methods used to reimburse and evaluate the cost-effectiveness of therapies, as well as challenges associated with applying these in the context of innovative therapies for rare diseases.
Original languageEnglish
TypeEvidence Base feature
Media of outputThe Evidence Base Online
Place of PublicationLondon
Publication statusPublished - 14 Oct 2020

Keywords

  • pricing
  • innovative therapies
  • pharmacoeconomics

Cite this